MEDIVIR AB – INTERIM REPORT

JANUARY – JUNE 2026

”With three Phase II studies funded, FLEX-HCC recruitment on track, and MIV-711 expanded into a second rare bone indication, Medivir is in its strongest position in many years”

April – June

Financial summary for the quarter

- Net turnover amounted to SEK 1.2 (1.5) million.
- Earnings before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -21.2 (-22.5) million. Basic and diluted earnings per share amounted to SEK -0.04 (-0.20).
- Cash flow from operating activities amounted to SEK -18.3 (-26.2) million.
- Cash and cash equivalents at the end of the period amounted to SEK 253.5 (38.2) million.

Significant events during the quarter

- At the Annual General Meeting on May 7, Anders Hallberg (Chairman), Angelica Loskog and Anna Törner were re-elected as board members. Kristian Tryggvason was newly elected.
- In May, the first patient was included in FLEX-HCC, the randomized phase 2 study of fostrox + lenvatinib compared with lenvatinib in second-line advanced liver cancer.
- In June, the phase 1b/2a results for fostrox + lenvatinib were published in Clinical Cancer Research.
- In June, the Board resolved on a directed share issue of approximately SEK 140 million, primarily to finance clinical development of MIV-711 in Legg-Calvé-Perthes disease (Perthes disease).

January – June

Financial summary for the period

- Net turnover amounted to SEK 2.3 (2.1) million.
- Earnings before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -29.9 (-35.1) million. Basic and diluted earnings per share amounted to SEK -0.06 (-0.32).
- Cash flow from operating activities amounted to SEK -31.3 (-53.0) million.
- Cash and cash equivalents at the end of the period amounted to SEK 253.5 (38.2) million.

Significant events after the end of the period

- At the Extraordinary General Meeting on July 20, the issue of 6,097,560 ordinary shares to Hallberg Management AB (Tranche 2) was approved, completing the SEK 140 million directed share issue.
- In July, Medivir received a Notice of Allowance from the USPTO for the combination patent covering fostrox plus lenvatinib in hepatocellular carcinoma (HCC) and liver metastases. Once granted, it provides protection and market exclusivity until at least April 2041.
- As of July 31, 2026, Medivir had 626,487,237 shares in total, of which 624,037,074 were ordinary shares and 2,450,163 were C shares.

Medivir in brief

Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease) and Perthes disease (idiopathic degeneration of the femoral head in children). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com

CEO's message

The second quarter marks a clinical and financial turning point for Medivir. The phase 1b/2a results for fostrox + lenvatinib were published in one of oncology's most cited journals, while the first patient was included in the FLEX-HCC study. Through an oversubscribed directed share issue of approximately SEK 140 million, we are able to expand MIV-711 into a second rare bone indication (Perthes disease) – and secure the funding for all three phase 2 studies. With a strengthened financial base and three high-potential indications, Medivir is well positioned to create substantial value, for affected patients and for our shareholders.

FLEX-HCC progressing according to plan – the unmet medical need remains

In May, the first patient was included in FLEX-HCC, the randomized phase 2 study comparing fostrox + lenvatinib with lenvatinib monotherapy in the second-line treatment of advanced liver cancer. The study is led by Professor Hong Jae Chon within the Korean Cancer Study Group and is conducted at 12 major hospitals in South Korea. Engagement among the clinicians is high, and the study is developing in line with the plan to include all patients within 12 months.

In June, the phase 1b/2a results for fostrox + lenvatinib were published in Clinical Cancer Research – a peer-reviewed confirmation that the liver-targeted mechanism of action of fostrox delivers tumor-selective efficacy without impairing liver function. The fact that the IMbrave 251 study, presented at ASCO, missed its primary endpoint underlines how substantial the unmet medical need still is after immunotherapy, and how promising the opportunity is for fostrox to become the first approved option in the second-line treatment of advanced liver cancer.

Osteogenesis Imperfecta (OI) – study design finalized

Preparations for the proof-of-concept study with MIV-711 in OI are progressing favorably. The study design has been finalized in close collaboration with our scientific expert council, and feasibility work is well under way. Interest from investigator sites is strong, and the first five sites have already been identified.

The potential is substantial: approximately 500,000 patients globally have no approved treatment, and the market is estimated to at least USD 2.5 billion.

MIV-711 expanded into Perthes disease

Through the directed share issue in June, we are initiating the clinical development of MIV-711 in Perthes disease, a rare condition in which the femoral head degenerates in children. There is no medical treatment for this disease; bracing and surgery address only the acute symptoms without changing the long-term prognosis.

MIV-711 has already been granted Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA in Perthes disease, and upon marketing approval in the U.S. and Europe, annual peak sales are estimated to reach approximately USD 1 billion five years after launch. Building two rare bone indications on the same established safety profile multiplies the value within a single drug candidate.

Stronger organization, financing and patent protection

To ensure maximum momentum in the MIV-711 programs, we have recruited a highly experienced Clinical Operations Lead with responsibility for the operational leadership and clinical execution of the studies in both OI and Perthes disease.

The directed share issue announced in June was oversubscribed and brought in new institutional investors – Cicero Fonder and Storebrand – alongside continued support from Carl Bennet, Hallberg Management, LINC and Nordea Småbolagsfond Norden. As a result, we now have financing in place for all three phase 2 studies.

In July, we also received a Notice of Allowance from the U.S. Patent and Trademark Office for the combination patent covering fostrox plus lenvatinib. Once the patent is granted, we will – together with the approvals in the EU, Japan, Australia and Canada – have protection in our key markets until April 2041.

Value drivers in the second half of the year

We enter the second half of the year with three clear value drivers: patient recruitment in FLEX-HCC, the preparations for proof-of-concept studies with MIV-711 in both OI and Perthes disease, and results from Vetbiolix's study of MIV-701 in canine periodontitis, which could generate royalty revenues for Medivir without material development costs of our own.

I would like to thank new and existing shareholders for the confidence that makes all of this possible, and I look forward to keeping you updated on the company's progress and value-creating opportunities ahead.

Jens Lindberg
Chief Executive Officer

Proprietary project



PROPRIETARY PROJECTS

Fostroxacitabine bralpamide (fostrox) – *for the treatment of liver cancer.*
Fostrox is Medivir's proprietary drug for the treatment of liver cancer. Fostrox is a liver-targeted inhibitor of DNA replication that selectively kills cancer cells in the liver, while minimizing systemic exposure to reduce side effects.

Fostrox's mechanism of action, inhibition of cancer cells' DNA replication and induction of DNA damage and cell death, is well proven in cancer therapy. Furthermore, Fostrox's prodrug design is a proven strategy for effectively delivering active substance to the liver, a mechanism successfully proven for example in antiviral treatment of hepatitis C.

Fostrox has received Orphan Drug Classification (ODD), both in the US and in the EU, for the treatment of hepatocellular carcinoma (HCC).

Primary liver cancer is the third leading cause of cancer-related deaths worldwide[1)] and the fastest growing form of cancer in the United States. Although existing treatments for advanced liver cancer can extend the lives of patients, far from all patients respond to treatment and unfortunately, mortality remains at a high level.

Phase 1a/1b monotherapy
Fostrox has been evaluated both as monotherapy and in combination with Lenvima (lenvatinib) or Keytruda (pembrolizumab), as a novel, oral drug candidate designed to maximize hepatic exposure while minimizing systemic side effects.

In the first part of the study, Phase 1a, safety and tolerability were evaluated at different doses of fostrox as monotherapy to establish dose levels for the Phase 1b monotherapy portion. A total of nineteen patients with various types of advanced liver cancer were included. This phase established safety and tolerability across escalating doses, with clinical proof-of-concept for fostrox monotherapy, including biopsy-confirmed selective induction of DNA damage in tumor cells. The determined monotherapy dose formed the basis for the starting dose in the Phase 1b combination portion of the study.
The results of the study were published in October 2024 in the Journal of Hepatocellular Carcinoma.

Combination study in phase 1b
In the phase 1b combination part of the study, fostrox was initially given in combination with two other drugs, either Lenvima® or Keytruda®, to patients with advanced HCC, where first-line therapy was no longer effective or tolerable. The aim of the study was to evaluate the safety, tolerability and clinical benefit of fostrox. Patients were included at 15 sites in the UK, Spain and South Korea. The dose escalation part (phase 1b) of the Keytruda combination established a safe dose, but for strategic reasons, Medivir chose to focus on the fostrox and Lenvima combination in the expansion part of the phase 2a study.

The dose escalation part (phase 1b) of the Lenvima combination was completed in February 2023. Preliminary results were positive with a good safety and tolerability profile and no dose-limiting toxicity observed. The recommended phase 2 dose for fostrox could be determined to 30 mg for 5 days in 21-day cycles. This dose was used in the expansion part (phase 2a) of the study.

Combination study in phase 2a
Patients in the phase 2a study with fostrox in combination with Lenvima were included between March and August 2023. In November 2024, the phase 1b/2a study of fostrox + Lenvima in advanced liver cancer was completed and remaining patients in the study were transferred to a compassionate use program.

At several scientific congresses in 2024, Medivir presented study data from Phase 1b/2a that consistently showed promising tumor control and good tolerability. The study's final safety and efficacy data were published in Clinical Cancer Research in June 2026.

The results in summary

The 21 patients in phase 1b/2a who received fostrox, in combination with Lenvima, had a median age of 63 years and 86% had received Tecentriq/Avastin as prior therapy. 19% of patients had received two prior therapies and 67% had metastases outside the liver. The median follow-up time was 10.5 months. The treatment demonstrated good safety and tolerability, with only one patient terminating the study due to adverse events related to fostrox. The median time to progression (TTP) was 10.9 months, significantly longer than previously seen in second-line treatment of advanced liver cancer, and the median overall survival (OS) was 13.7 months. The combination showed an Objective Response Rate (ORR) of 24% with a median duration of response of 7 months. Tumor shrinkage was noted in >75% of patients and clinical benefit from treatment lasted on average 11.3 months[2)].

In summary, these data provide strong support for the FLEX-HCC study in second-line advanced liver cancer, where the combination of fostrox and lenvatinib is compared with lenvatinib monotherapy.

FLEX-HCC investigator-sponsored phase 2 study initiated

The first patient in the randomized phase 2 study was dosed in May 2026. Engagement among the participating hospitals is high and enrollment is progressing in line with the plan to include all patients within 12 months. Patients included in the study have: 1) locally advanced or metastatic primary liver cancer; 2) already received an immunotherapy combination; and 3) a liver function that is adequate for this type of treatment (Child-Pugh A). The study is conducted in collaboration with the Korean Cancer Study Group at 12 hospitals in South Korea, with Professor Hong Jae Chon as principal investigator. Patients are randomized to receive either fostrox + lenvatinib or lenvatinib monotherapy and are followed to evaluate the primary efficacy endpoint, objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), time to progression (TTP) and overall survival (OS). Every six weeks, an evaluation of response/disease progression is carried out using MRI and/or CT.

MIV-711 – *selective cathepsin K inhibitor with the potential to become the first disease-modifying treatment for Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (Perthes disease).*

In November 2025, MIV-711 received Orphan Drug Designation (ODD) from the FDA for the treatment of Osteogenesis Imperfecta, a rare genetic disease that affects the body's ability to produce type I collagen and leads to bone fragility, pain, skeletal deformities, and frequent fractures, often occurring without prior trauma. There is a significant unmet medical need for new treatments as there are currently no approved medications available.

The next planned step in the development of MIV-711 is to conduct a clinical proof-of-concept study in adult patients with the disease, to confirm the positive effects on bone quality and bone strength observed in a disease-specific animal model. The clinical development of MIV-711 has the potential to open up a market at least comparable to that of the company's drug candidate fostrox in primary liver cancer.

In April 2024, MIV-711 received Rare Pediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) from the FDA for the treatment of Perthes disease, a rare and serious hip disorder affecting children between the ages of 2 and 12. For Perthes disease, too, there are no approved drug treatments available.

The next planned step in the development of MIV-711 in Perthes disease is to develop a pediatric formulation and to conduct a randomized proof-of-concept study, to confirm the positive effect in counteracting deformity of the femoral head already demonstrated in a disease-specific animal model. In Perthes disease, MIV-711 is assessed to have the potential to generate annual sales of approximately USD 1 billion five years after marketing approval.

Additional support for the disease-modifying effects of MIV-711 comes from Medivir's Phase II study demonstrating positive effects on both bone and cartilage in the knee joints of osteoarthritis patients after just six months of treatment.
The study showed a significant difference, with preservation of cartilage and reduced bone erosion in patients treated with MIV-711 compared with placebo, and had a good tolerability and safety profile.

1) https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
2) *Chon et al., Clinical Cancer Research, 2026*

Projects for partnering



PROJECTS FOR PARTNERING

Medivir has two projects for licensing/partnership: **Birinapant –** *for the treatment of solid tumors* and **USP-7 –** *for the treatment of cancer*

In 2025, it was announced that IGM Biosciences had been acquired by Concentra Biosciences. Subsequently, birinapant was returned to Medivir. At present, Medivir is not conducting any active clinical development of birinapant but is instead seeking to enter into licensing or partnership agreements for its continued clinical development.

In February 2022, a licensing agreement was entered into with the UK-based Ubiquigent Limited for the preclinical USP-7 program. Unfortunately, funding challenges have made it impossible for Ubiquigent to continue operations. Medivir is currently evaluating the path forward for the USP-7 project.

Outlicensed projects



OUTLICENSED PROJECTS

Xerclear® (Zoviduo®) was approved in 2009 for the treatment of labial herpes (cold sores). The marketing rights to Xerclear in the USA, Canada and Mexico were divested in 2010. The rights in Europe and the rest of the world have been out-licensed to Haleon, with the exception of China, where Medivir has out-licensed the rights to Shijiazhuang Yuanmai Biotechnology (SYB), and Israel and South America, where Medivir has retained the rights.

Medivir receives royalties on Xerclear (Zoviduo) sales from Haleon. In addition, Medivir would receive milestones when Zoviduo is approved as an over-the-counter product in new markets.

After marketing approval in China, Medivir will receive a fixed royalty from SYB for each unit sold and the agreement guarantees a minimum sale during the first three years on the market amounting to single-digit million SEK.

Remetinostat

In October 2025, an exclusive license agreement was signed with Biossil Inc, giving them global, exclusive development rights for remetinostat. The terms of the agreement entitle Medivir to milestone payments of up to approximately USD 60 million, subject to the successful development and approval of remetinostat, in addition to royalties in the mid-single digits on future net sales.

Remetinostat, for the treatment of various forms of skin cancer, is a histone deacetylase (HDAC) inhibitor administered topically as a gel. It is rapidly metabolized

upon reaching the bloodstream, thereby reducing the risk of side effects typically associated with HDAC inhibitors. Three phase II studies with remetinostat have been conducted - in cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (SCC). Remetinostat has shown positive clinical efficacy and acceptable tolerability without systemic side effects in these three types of skin cancer and in different histological subtypes.

MIV-701

Medivir's selective cathepsin K inhibitor MIV-701 has suitable properties for veterinary use and was out-licensed to the French company Vetbiolix in 2019.

In April 2024, Vetbiolix reported positive results from a clinical Proof-of-Concept study in canine periodontitis (gum disease) with its drug candidate VBX-1000 (MIV-701). In November 2025, Vetbiolix announced the publication of strong clinical Proof-of-Concept study results for VBX-1000 in the journal Frontiers in Veterinary Science.

Vetbiolix has initiated a phase 2 study to confirm the positive effect of VBX-1000 (MIV-701) demonstrated in the groundbreaking proof-of-concept study. At the end of the quarter, the study had included 29 of a total of 51 dogs, and clinical results are expected in the fourth quarter of 2026.

Periodontitis is one of the most common health problems in dogs. Only the very earliest stage of the disease is reversible; once bone loss has occurred, it cannot be restored. Halting bone loss as early as possible is therefore critical to preventing disease progression.

The disease affects approximately 80 percent of all dogs over three years of age, representing a substantial proportion of the pet population. There are currently around 90 million companion dogs in the United States and approximately 70 million in the EU.

Despite this significant medical need, there are currently no approved drugs capable of stopping or reducing alveolar bone resorption when periodontitis occurs. This represents a substantial commercial opportunity for VBX-1000 (MIV-701).

Under the agreement, Medivir retains a substantial financial upside through future royalties on net sales as well as a significant portion of potential partnership payments from collaborations with third parties.

Preclinical project

MBLI/MET-X

Medivir's metallo-beta-lactamase (MBLI)/MET-X program aimed at addressing the threat of resistant bacteria was out-licensed in 2017 to the AMR Centre (today Infex Therapeutics) in England. Infex received QIDP-designation (Qualified Infectious Disease Product) from the FDA in 2023 and has communicated its intention to initiate a phase 1 program for MET-X. In February 2025, Infex announced that it had signed a license agreement for the clinical development of MET-X in India. Medivir is entitled to a share of the future revenues generated by the collaboration.

Project descriptions

Full descriptions of all of Medivir's development projects, including their current status and ongoing studies, can be found on the Medivir website: https://www.medivir.com/our-projects

Financial overview, April-June 2026

Summary of the Group's figures	Q2		Q1 - Q2		Full Year
(SEK m)	2026	2025	2026	2025	2025
Net turnover	1.2	1.5	2.3	2.1	8.5
Operating profit before depreciation and amortization (EBITDA)	-21.2	-22.5	-29.9	-35.1	-60.1
Operating profit (EBIT)	-21.2	-23.2	-30.6	-36.5	-92.6
Profit/loss before tax	-20.1	-23.3	-29.5	-36.6	-94.4
Basic earnings per share, SEK	-0.04	-0.20	-0.06	-0.32	-0.66
Diluted earnings per share, SEK	-0.04	-0.20	-0.06	-0.32	-0.66
Net worth per share, SEK	0.48	0.69	0.48	0.69	0.34
Return on equity, %	-33.0	-102.4	-26.1	-75.0	-69.7
Cash flow from operating activities	-18.3	-26.2	-31.3	-53.0	-73.3
Cash and cash equivalents at period end	253.5	38.2	253.5	38.2	119.2

Revenues
Net turnover for the period from April - June 2026 was SEK 1.2 (1.5) million, reflecting lower royalty revenues.

Operating expenses
Other external costs totalled SEK -17.9 (-17.0) million, an increase of SEK 0.9 million which relates to higher costs for clinical studies.

Personnel costs amounted to SEK -4.3 (-7.1) million, a decrease of SEK 2.7 million compared with the same period last year. Total operating expenses amounted to SEK -22.4 (-24.9) million, a decrease of SEK 2.5 million.

Operating profit/loss
The operating loss totalled SEK -21.2 (-23.2) million, an improvement of SEK 2.0 million, mainly attributable to lower personnel costs.

Cash flow, investments, and financial position
Liquid assets, including short-term investments with a maximum term of three months, amounted to SEK 253.5 (38.2) million at the end of the period, an increase of SEK 215.3 million. The opening balance for 2026 was SEK 119.2 (62.5) million.

Cash flow from operating activities totalled SEK -18.3 (-26.2) million, with changes in working capital accounting for SEK 1.0 (-3.7) million of this total.

The period's investments in tangible and intangible fixed assets totalled SEK 0.0 (0.0) million.

Cash flow from financing activities totalled SEK 122.7 (29.3) million.

Financial overview, January-June 2026

Revenues
Net turnover for the period was SEK 2.3 (2.1) million. The increase derives from higher royalty revenues.

Operating expenses
Other external costs totalled SEK -22.4 (-23.2) million, a decrease of SEK 0.8 million, driven by lower costs for clinical studies.

Personnel costs amounted to SEK -9.8 (-14.1) million, a decrease of SEK 4.2 million compared with the same period last year. Total operating expenses amounted to SEK -33.0 (-39.1) million, a decrease of SEK 6.0 million.

Operating profit/loss
The operating loss totalled SEK -30.6 (-36.5) million, an improvement of SEK 5.9 million, mainly attributable to lower personnel costs.

Cash flow, investments, and financial position
Liquid assets, including short-term investments with a maximum term of three
months, amounted to SEK 253.5 (38.2) million at the end of the period, an increase of SEK 215.3 million. The opening balance for 2026 was SEK 119.2 (62.5) million.

Cash flow from operating activities totalled SEK -31.3 (-53.0) million, with changes in working capital accounting for SEK -4.3 (-18.7) million of this total.

The period's investments in tangible and intangible fixed assets totalled SEK 0.0 (0.0) million. Cash flow from financing activities totalled SEK 165.6 (28.7) million

Other disclosures, January - June 2026

Employees
Medivir had 6 (10) employees (FTEs) at the end of the period, 67% (60%) of whom were women. Out of these employees, there is 1 (0) who has been given notice of termination of employment, but whose employment has not yet been terminated.

Share and related plans
In June, Medivir carried out a directed new share issue of approximately SEK 140 million to enable the clinical development of the drug candidate MIV-711 for the treatment of Legg-Calvé-Perthes disease. In the directed new share issue, 85,365,854 ordinary shares were subscribed.

Number of shares	Ordinary Shares	C shares	Total Shares
No. of shares January 1, 2026	**448 671 220**	**2 450 163**	**451 121 383**
Direct issue shares	90 000 000	0	90 000 000
Direct issue shares	79 268 294	0	79 268 294
No. of shares June 30, 2026	**617 939 514**	**2 450 163**	**620 389 677**

Medivir's holdings amount to 2,450,163 own C shares in the company.

Board Program – In May 2025, the board of directors and the annual general meeting approved an incentive program in the form of a share price-related program for variable remuneration to the members of the board. The remuneration under the Board Program is to be determined based on the share price development during a measurement period of approximately one year, commencing on May 7, 2026 (the "start date") and ending on the day immediately preceding the annual general meeting held in 2027 (the "end date") (the "Measurement Period"). Participants in the Board Program receive a variable cash remuneration calculated by multiplying the percentage share price development during the Measurement Period by the participant's board fee during the Measurement Period. The maximum remuneration under the Board Program amounts to 200 percent of the participant's board fee during the Measurement Period. If the share price development during the Measurement Period is negative or equal to zero, no variable remuneration is paid under the Board Program.

Share savings program - At the beginning of the period, there were 231,750 investment shares in ongoing share savings programs. Total outstanding investment shares at the end of the period amounted to 199,750.

LTIP 2023
In May 2023, the board of directors and the annual general meeting approved a long-term incentive program in the form of a share matching scheme. For each investment share, participants are entitled, provided that certain conditions are met, to receive one (1) ordinary share free of charge under the LTIP 2023 ("matching shares") and, in addition, provided that certain performance conditions are met, a maximum of five (5) additional ordinary shares ("performance shares") free of charge in accordance with the terms of the program. 105,750 investment shares have been acquired under the LTIP 2023 at a price of SEK 7.34 per share. The vesting period runs until the publication of the interim report for January–March 2026. Following a recalculation prompted by rights issues during 2023 and 2025, each investment share entitles the holder to 1.22 ordinary shares.

LTIP 2023 was terminated in connection with the publication of the interim report for the first quarter of 2026. The conditions for receiving performance shares under LTIP 2023 were not met. The participants in the program were allotted a total of 108,328 matching shares in accordance with the terms and conditions of the program.

LTIP 2024
In May 2024, the board of directors and the annual general meeting approved a long-term incentive program in the form of a share matching scheme. For each investment share, participants have the opportunity, provided certain conditions are met, to receive one (1) ordinary share free of charge under the LTIP 2024 ("matching shares") and, in addition, provided that certain performance conditions are met, a maximum of five (5) additional ordinary shares ("performance shares") free of charge in accordance with the terms of the program. 126,000 investment shares have been acquired under the LTIP 2024 at a price of SEK 2.94 per share. The vesting period runs until the publication of the interim report for January–March 2027. Following a recalculation prompted by the rights issue during 2025, the number of matching shares and performance shares per investment share remains unchanged.

Currency exposure
In accordance with Medivir's financial policy, the need for currency hedging is evaluated on an ongoing basis. In general, the group has not used currency hedging, which means that income and costs have been affected by fluctuations in foreign exchange rates. All foreign currency transactions have taken place at the best exchange rate obtainable at the time of each transaction. Many of Medivir's contracts involve payment in EUR, CHF, USD and GBP, which means that

accounts payable and receivable carry a currency exposure.

The Parent Company in brief

Medivir AB (publ), corporate ID no. 556238-4361, is the Parent Company of the Group. Its operations consist of pharmaceutical development, administrative and company management functions. At the end of 2025, Medivir AB sold the MIV-711 project to its newly established wholly owned subsidiary, OsteoCat Therapeutics AB, where the project is recognized as an intangible asset.

The Parent Company's total turnover amounted to SEK 2.3 (2.1) million.

Total operating expenses totalled SEK -31.2 (-39.1) million, a decrease of SEK 7.9 million.

The operating profit/loss was SEK -28.7 (-36.8) million, an improvement of SEK 8.1 million.

Net financial items totalled SEK 1.2 (0.2) million. The tax for the period totalled SEK 0.0 (0.0) million. The net loss for the period was SEK -27.5 (-36.6) million, an improvement of SEK 9.1 million, mainly due to lower operating expenses. Liquid assets, including short-term investments with a maximum term of three months, amounted to SEK 249.0 (38.2) million.

Transactions with related parties

During the period, no transactions with related parties were carried out except for board fees.

Significant risks and uncertainty factors

The process of pharmaceutical research and development, through to regulatory approval, is both high-risk and capital-intensive – the majority of projects initiated will never achieve regulatory approval. If competing pharmaceuticals take market share, or competing research projects achieve better efficacy and reach the market more quickly, the future value of Medivir's product and project portfolio may be lower than expected. Medivir's success in developing medicines, entering into partnerships, and securing funding for its operations is decisive for shareholder value.

In addition to industry-specific risk factors, there is added uncertainty in the broader global environment, including Russia's invasion of Ukraine, unrest in the Middle East, and global trade tensions. Although central banks currently appear to have inflation under control, there is still a risk that political and geopolitical conflicts may negatively impact the economy and inflation.

A more detailed description of the exposure to risk, and of the ways in which Medivir manages it, is provided in the 2025 Annual Report on pages 26-27 and 35, and in Note 7 on pages 50-52. The Annual Report is available on the company's website: www.medivir.com.

Outlook

The directed share issue of approximately SEK 134 million net in June/July has significantly strengthened the company's financial position, and Medivir is now well financed, with liquid assets of more than a quarter of a billion Swedish kronor. Given the company's current project portfolio, the Board of Directors and management assess that existing cash resources are sufficient at least into 2030. This assessment does not take into account positive cash flow from any out-licensing of fostrox and MIV-711, or from the existing partnership agreements with Vetbiolix regarding MIV-701 and with Biossil regarding remetinostat.

The Board of Directors and the President & CEO hereby affirm that the Interim Report constitutes a faithful representation of the company's and the Group's operations, position and profit/loss, and that it describes the significant risks and uncertainty factors faced by the company and the companies that make up the Group.

Huddinge, August 20, 2026

Anders Hallberg Chairman of the Board	Angelica Loskog Member of the Board	Kristian Tryggvason Member of the Board
Anna Törner Member of the Board	Jens Lindberg Chief Executive Officer	

This report has not been subject to auditors' review.

This information is information that Medivir is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08.30 CEST on August 20, 2026.

For further information, please contact:
Jens Lindberg, CEO, +46 8-546 831 00.

Conference call for investors, analysts and the media
The Interim Report January – June 2026 will be presented by Medivir's CEO, Jens Lindberg.

Time: Thursday, August 20, at 14.00 (CEST).

To call in to the conference - Please register here!
If you wish to participate via webcast - Please use this link!

The conference call will also be streamed via a link on the website: www.medivir.com/investors/calendar

The presentation will be available on Medivir's website after completion of the conference.

Contact the Nomination Committee:
Shareholders who wish to submit proposals to the nomination committee can send the proposal by email to: valberedning@medivir.se

Financial calendar:
Interim Report (January-September 2026)
November 5, 2026
Year-End Report (January-December 2026)
February 18, 2027
Interim Report (January-March 2027)
April 29, 2027

Notes

Accounting principles
Medivir prepares its Consolidated Accounts in accordance with IFRS, International Financial Reporting Standards, as endorsed by the EU. In addition to the stated IFRS, the Group also applies the Swedish Financial Reporting Board's recommendation, RFR 1 Supplementary Accounting Rules for Groups, the Annual Accounts Act and applicable statements from the Swedish Financial Reporting Board. The Group applies the historical cost method for balance sheet valuations, unless otherwise stated. The parent company's financial statements are prepared in accordance with the Annual Accounts Act and RFR 2

Accounting for Legal Entities. The interim report has been prepared in accordance with IAS 34.

Regarding the introduction of IFRS 18, Presentation and Disclosures in Financial Statements will become applicable for financial years beginning on or after January 1, 2027. The standard will replace IAS 1, Presentation of Financial Statements, and introduce new requirements aimed at enhancing comparability in financial performance reporting for similar companies while providing users with more relevant information and transparency.

IFRS 18 will not affect the recognition or measurement of items in the financial statements, meaning it will have no impact on net profit.

Management initiated an assessment during 2025 of the implications of applying the new standard. No other standards, amendments, or interpretations of standards that have not yet come into effect are expected to have a material impact on Medivir's financial statements. See pages 42-47 of the 2025 Annual Report for a full presentation of the accounting principles applied by the Group. There have been no changes in accounting principles since the 2025 Annual Report was published. Rounding may mean that certain tables do not add up.

Consolidated Income Statement, summary

	Q2		Q1 - Q2		Full year
(SEK m)	2026	2025	2026	2025	2025
Net turnover	1.2	1.5	2.3	2.1	8.5
Other operating income	0.0	0.3	0.2	0.5	0.4
Total income	**1.2**	**1.8**	**2.5**	**2.6**	**8.9**
Other external expenses	-17.9	-17.0	-22.4	-23.2	-41.4
Personnel costs	-4.3	-7.1	-9.8	-14.1	-27.1
Depreciations and write-downs	0.0	-0.7	-0.6	-1.4	-32.5
Other operating expenses	-0.2	-0.2	-0.2	-0.5	-0.5
Operating profit/loss	**-21.2**	**-23.2**	**-30.6**	**-36.5**	**-92.6**
Net financial items	1.1	-0.2	1.1	-0.1	-1.8
Profit/loss after financial items	**-20.1**	**-23.3**	**-29.5**	**-36.6**	**-94.4**
Tax	-	-	-	-	-
Net profit/loss for the period	**-20.1**	**-23.3**	**-29.5**	**-36.6**	**-94.4**
Net profit/loss for the period attributable to:					
Parent Company shareholders	-20.1	-23.3	-29.5	-36.6	-94.4
Earnings per share, calculated from the net profit/loss attributable to Parent Company shareholders during the period					
Earnings per share (SEK per share)					
- Total operations, basic earnings	-0.04	-0.20	-0.06	-0.32	-0.66
- Total operations, diluted earnings	-0.04	-0.20	-0.06	-0.32	-0.66
Average number of shares, '000	567 544	114 618	524 333	114 618	142 660
Average number of shares after dilution '000	567 544	114 618	524 333	114 618	142 660
Number of shares at period end, '000	620 390	114 618	620 390	114 618	451 121

Consolidated Statement of Comprehensive Income

	Q2		Q1 - Q2		Full year
(SEK m)	2026	2025	2026	2025	2025
Net profit/loss for the period	**-20.1**	**-23.3**	**-29.5**	**-36.6**	**-94.4**
Other comprehensive income					
Exchange rate differences	-	-	-	-	-
Total other comprehensive income	**-**	**-**	**-**	**-**	**-**
Total comprehensive income for the period	**-20.1**	**-23.3**	**-29.5**	**-36.6**	**-94.4**

Consolidated Balance Sheet, summary

(SEK m)	30-jun 2026	30-jun 2025	31-dec 2025
Assets			
Intangible fixed assets	66.5	96.3	66.5
Tangible fixed assets	5.7	8.3	6.9
Current receivables	5.5	4.0	4.5
Short-term investments	241.1	7.1	87.3
Cash and cash equivalents	12.4	31.1	31.9
Total assets	**331.2**	**146.9**	**197.2**
Shareholders' equity and liabilities			
Shareholders' equity	295.8	79.6	155.2
Provisions	0.5	-	-
Long-term liabilities	4.5	7.4	8.2
Current liabilities	30.5	59.9	33.8
Total shareholders' equity and liabilities	**331.2**	**146.9**	**197.2**

Consolidated Statement of Changes in Equity

(SEK m)	Share capital	Other paid-in capital	Exchange rate difference	Accum. loss	Total equity
Opening balance, 1 January 2025	**57.3**	**926.0**	**-3.3**	**-864.5**	**115.5**
Total comprehensive income for the period	-	-	-	-94.4	-94.4
Reduction of share capital	-40.1	40.1	-	-	-
Directed new issue	50.5	101.0	-	-	151.4
Transaction costs	-	-	-	-18.7	-18.7
Share savings program	-	-	-	1.4	1.4
Closing balance, 31 December 2025	**67.7**	**1 067.1**	**-3.3**	**-976.2**	**155.2**
Opening balance, 1 January 2026	**67.7**	**1 067.1**	**-3.3**	**-976.2**	**155.2**
Total comprehensive income for the period	-	-	-	-29.5	-29.5
Share issue	25.4	144.8	-	-	170.2
Share savings program	-	-	-	0.7	0.7
Transaction costs	-	-	-	-0.8	-0.8
Closing balance, 30 June 2026	**93.1**	**1 211.9**	**-3.3**	**-1 005.9**	**295.8**

Consolidated Cash Flow Statement, summary

(SEK m)	Q2 2026	Q2 2025	Q1 - Q2 2026	Q1 - Q2 2025	Full Year 2025
Cash flow from operating activities before changes in working capital	**-19.3**	**-22.5**	**-27.0**	**-34.3**	**-58.4**
Changes in working capital	1.0	-3.7	-4.3	-18.7	-15.0
Cash flow from operating activities	**-18.3**	**-26.2**	**-31.3**	**-53.0**	**-73.3**
Investing activities					
Acquisition/sale of fixed assets	-	-	-	-	-
Cash flow from investing activities	**-**	**-**	**-**	**-**	**-**
Financing activities					
Loans raised	-	30.0	-	30.0	-
Other changes in longterm receivables/liabilities	-1.9	-0.7	-3.7	-1.3	-2.7
New share issue	125.2	-	170.2	-	151.4
Transaction costs	-0.6	-	-0.9	-	-18.7
Cash flow from financing activities	**122.7**	**29.3**	**165.6**	**28.7**	**130.0**
Cash flow for the period	**104.4**	**3.1**	**134.3**	**-24.3**	**56.7**
Cash and cash equivalents at beginning of period	149.1	35.1	119.2	62.5	62.5
Cash and cash equivalents at end of period	**253.5**	**38.2**	**253.5**	**38.2**	**119.2**

Parent company income statement, summary

(SEK m)	Q2 2026	Q2 2025	Q1 - Q2 2026	Q1 - Q2 2025	Full year 2025
Net turnover	1.2	1.5	2.3	2.1	117.8
Other operating income	0.0	0.3	0.2	0.2	2.1
Total income	**1.2**	**1.8**	**2.5**	**2.3**	**119.9**
Other external expenses	-16.1	-17.9	-21.2	-24.8	-44.7
Personnel costs	-4.3	-7.1	-9.8	-14.1	-27.1
Depreciations and write-downs	-	0.0	-	-0.1	-29.9
Other operating expenses	-0.1	-0.2	-0.1	-0.2	-0.5
Operating profit/loss	**-19.4**	**-23.3**	**-28.7**	**-36.8**	**17.8**
Profit/loss from participation in Group companies	-	-	-	-	-
Net financial items	1.1	0.0	1.2	0.2	-1.2
Profit/loss after financial items	**-18.3**	**-23.3**	**-27.5**	**-36.6**	**16.6**
Tax	-	-	-	-	-
Net profit/loss for the period (=comprehensive income)	**-18.3**	**-23.3**	**-27.5**	**-36.6**	**16.6**

Parent company balance sheet, summary

(SEK m)	30-jun 2026	30-jun 2025	31-dec 2025
Assets			
Intangible fixed assets	66.5	96.3	66.5
Shares in subsidiaries	109.4	0.1	109.4
Current receivables	11.1	4.9	5.4
Short-term investments	241.1	7.1	87.3
Cash and bank balances	7.9	31.1	31.9
Total assets	**435.9**	**139.5**	**300.3**
Shareholders' equity and liabilities			
Shareholders' equity	409.3	80.2	266.8
Provisions	0.5	-	2.4
Liabilities to Group companies	-	1.8	-
Current liabilities	26.1	57.5	31.2
Total shareholders' equity and liabilities	**435.9**	**139.5**	**300.3**

Key ratios, share data

	Q2 2026	Q2 2025	Q1 - Q2 2026	Q1 - Q2 2025	Full year 2025
Return on:					
- shareholders' equity, %	-33.0	-102.4	-26.1	-75.0	-69.7
- capital employed, %	-32.0	-79.2	-25.1	-58.7	-63.4
- total capital, %	-28.8	-63.3	-22.2	-45.2	-49.8
Number of shares at beginning of period, '000	541 121	114 618	451 121	114 618	114 618
Number of shares at period end, '000	620 390	114 618	620 390	114 618	451 121
- of which ordinary shares	617 940	112 168	617 940	112 168	448 671
- of which repurchased C shares	2 450	2 450	2 450	2 450	2 450
Average number of shares, '000	567 544	114 618	524 333	114 618	142 660
Share savings program (investment shares), '000	200	232	200	232	232
Outstanding warrants, '000	-	525	-	525	-
Share capital at period end, SEK m	93.1	57.3	93.1	57.3	67.7
Shareholders' equity at period end, SEK m	295.8	79.6	295.8	79.6	155.2
Earnings per share, SEK					
- Total operations, basic earnings	-0.04	-0.20	-0.06	-0.32	-0.66
- Total operations, diluted earnings	-0.04	-0.20	-0.06	-0.32	-0.66
Shareholders' equity per share, SEK	0.48	0.69	0.48	0.69	0.34
Net worth per share, SEK	0.48	0.69	0.48	0.69	0.34
Cash flow per share after investments, SEK	-0.03	-0.23	-0.06	-0.46	-0.51
Equity/assets ratio, %	89.3	54.2	89.3	54.2	78.7
EBITDA	-21.2	-22.5	-29.9	-35.1	-60.1
EBIT	-21.2	-23.2	-30.6	-36.5	-92.6

Key ratio definitions

Average number of shares. The unweighted average number of shares during the period.
Basic earnings per share. Profit/loss after tax divided by the average number of shares.
Capital employed. Balance sheet total less non-interest-bearing liabilities including deferred tax liabilities.
Cash flow per share after investments. Cash flow after investments divided by the average number of shares.
Diluted earnings per share. Profit/loss after tax divided by the average number of shares and outstanding warrants adjusted for any dilution effect.
EBIT. Operating profit/loss after depreciation and amortization.
EBITDA. Operating profit/loss before depreciation and amortization.
Equity/assets ratio. Shareholders' equity in relation to the balance sheet total.
Net worth per share. Shareholders' equity plus unrealized gains/losses in listed securities divided by the number of shares at the period end.
Operating margin. Operating profit/loss as a percentage of net sales.
Return on capital employed. Profit/loss after financial items plus interest expenses as a percentage of the average capital employed.
Return on shareholders' equity. Profit/loss after tax as a percentage of the average shareholders' equity.
Return on total assets. Profit/loss after financial items plus interest expenses as a percentage of the average Balance Sheet total.
Shareholders' equity per share. Shareholders' equity divided by the number of shares at the end of the period.

The above key ratios are deemed to be relevant for the type of operations conducted by Medivir and to contribute to an increased understanding of the financial report.